Compare Enphase Energy Inc (ENPH) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Novartis AG — how do they compare? Enphase Energy Inc trades at $33.24 (market cap $4.43B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 61.9× Enphase Energy Inc's market cap, and Novartis AG pays a 3.31% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Novartis AG for 82 Days on average.
| ENPH | NVS | |
|---|---|---|
Market Cap | $4.43B | $274.00B |
Volume | 3,388,482 | 1,852,137 |
Sector | Energy | Health |
52-Week High | $72.33 | $168.62 |
52-Week Low | $26.12 | $121.80 |
Typical Hold Time | 72 Days | 82 Days |
Enterprise Value | $4.07B | $315.32B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.91, down 2.95% on the day, amid a bearish technical signal and mixed earnings history. The stock shows weakening revenue and net income from 2023 peaks, with 2025 revenue at $1.47B and net income of $172.13M. Recent news highlights volatility in solar stocks due to high borrowing costs, though Enphase advances with IQ Meter Collar approvals and solid-state transformer development for AI data centers.
Outlook is cautious; while analyst consensus targets $42.90 (30% upside), recent earnings misses and bearish technicals suggest near-term pressure. Risks include solar industry headwinds and execution challenges, but long-term growth potential exists in energy technology expansion. Investors should weigh valuation metrics like P/E of 33.17 against competitive and macroeconomic risks.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
